ARBOVAX

Arbovax will focus on the research and development of a unique and proprietary technology that can be used to make vaccines to target unmet clinical needs in markets that have traditionally been neglected by major vaccine producers. Arbovax intends to engage in the preclinical and clinical development of vaccine products for the prophylactic treatment of arthropod-borne diseases that collectively infect over 100 million people annually and put over 2.5 billion people at risk of infection. The b... usiness strategy of the Company is to develop the technology to a point where it can be licensed to commercial partners for manufacture and distribution. Arbovax’s patent-protected technology is based upon multiple deletions in the transmembrane portion of the virus allowing it to replicate in insect cells, but not in mammalian cells. This forms the basis for the creation of a family of vaccines that offer the following advantages:More